Category Archives: CLSA Home

Jennifer Doudna, Ph.D., to be Named Recipient of CLSA’s Life Sciences Leadership Award at 2019 Pantheon DiNA Awards

California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, has announced that Dr. Jennifer Doudna, a visionary leader in CRISPR gene editing technology and nominee for Nobel Prize in Chemistry, will receive the 2019 Life Sciences Leadership Award, a prestigious award to be presented at CLSA’s 2019 Pantheon DiNA Program. The Pantheon Awards honors California’s most innovative and dedicated life sciences leaders for their ongoing contributions to California’s life sciences sector.

CLSA Op-Ed in CALMatters: California leads the way in precision medicine

Precision medicine uses some of the world’s most sophisticated technologies to find the root causes of each patient’s unique condition and apply the best, most precise treatments. California is a biomedical juggernaut, and the precision medicine research being funded today will impact patients around the world. Learn how California is leading the way in precision medicine research.

CLSA Names 2019 Pantheon DiNA Award Winners, Recognizing Advancements in California Life Sciences

California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, has announced the 2019 Pantheon DiNATM Awards slate of honorees. Through the premier awards program, CLSA annually recognizes excellence in the California life sciences sector and celebrates the contributions and achievements of leading life sciences innovators in the state.

CLSA Opposes New Dangerous Price Controls Proposal Threatening California’s Biopharmaceutical Innovation Ecosystem

On Sept. 19, House Speaker Nancy Pelosi (D-San Francisco) unveiled legislation in the form of the Lower Drug Costs Now Act (H.R. 3), an unprecedented sweeping proposal that would transfer most domestic drug pricing decision-making to U.S. and European government bureaucrats, and eviscerate the free market model that has promoted innovation, cures and treatments for millions of patients.

CLSA Op-Ed in Morning Consult: Foreign Price Controls Will Stifle Medical Innovation and Hinder Patient Access

CLSA President & CEO Mike Guerra pens an op-ed in Morning Consult regarding the dangers of policymakers utilizing foreign price controls to lower drug costs. With growing bipartisan support for these schemes, CLSA is working to educate policymakers that importing price controls will do little to lessen the financial burden for patients. Rather, these short-sighted proposals will hinder access to needed treatments and discourage medical innovation in California.

CLSA Leadership & Member Companies Visit Capitol Hill to Urge Medical Device Tax Repeal

CLSA leadership participated in an executive advocacy day on Capitol Hill on Sept. 19, that was coordinated by our national medtech association partner, AdvaMed. The purpose of the fly-in was to advocate for the full and permanent repeal of the 2.3 percent excise tax on medical device revenue that will go back into effect on January 1, 2020 if Congress does not act before the end of the year.

CLSA Awaits Governor Newsom’s Decision on Numerous Bills

While fewer bills directly targeting the biopharmaceutical industry were introduced this year, which was likely due in large part to Governor Newsom’s executive order on state prescription purchasing, CLSA strongly supported several bills that reached the Governor’s desk and helped prevent a number of bills of concern from reaching his desk.